Sorafenib is a synthetic compound targeting growth signaling and angiogenesis. Sorafenib blocks the enzyme RAF kinase, a critical component of the RAF/MEK/ERK signaling pathway that controls cell division and proliferation; in addition, sorafenib inhibits the VEGFR-2/PDGFR-beta signaling cascade, thereby blocking tumor angiogenesis. Sorafenib was approved in 2005 for use in the treatment of advanced renal cancer.
Appearance & Physical State: White to off-white solid
Density: 1.454 g/cm3
Melting Point: 225-235ºC
Boiling Point: 523.3ºC at 760 mmHg
Flash Point: 270.3ºC
Vapor Pressure: 4.76E-11mmHg at 25°C